Synthesis and activity of a new class of pathway-selective estrogen receptor ligands: Hydroxybenzoyl-3,4-dihydroquinoxalin-2(1H)-ones
摘要:
The anti-inflammatory activity of non-selective estrogens has been attributed to their ability to antagonize the activity of nuclear factor KB (NF-kappa B), a known mediator of inflammatory responses. Here we report the identification of a potent new class of pathway-selective ER ligands that selectively antagonize NF-kappa B functional activity, while exhibiting a lack of classical estrogenic effect. (c) 2006 Elsevier Ltd. All rights reserved.
The present invention relates to estrogen receptor ligands, and compounds and methods for treating diseases associated with excessive estrogen receptor activity.
这项发明涉及雌激素受体配体,以及用于治疗与过度雌激素受体活性相关疾病的化合物和方法。
Quinoxalines, a process for their preparation and their use
申请人:Hoechst Aktiengesellschaft
公开号:US05723461A1
公开(公告)日:1998-03-03
Disclosed are quinoxalinone compounds of the formula I or Ia ##STR1## and physiologically tolerated salts and prodrugs thereof, in which n=zero, one or two; R.sup.1 =fluorine, chlorine, hydroxyl or C.sub.1 -C.sub.3 -alkoxy; R.sup.2 =C.sub.1 -C.sub.4 -alkyl which is unsubstituted or is substituted by hydroxyl, C.sub.1 -C.sub.4 -alkoxy or C.sub.1 -C.sub.4 -alkylthio; R.sup.3 =C.sub.1 -C.sub.6 -alkyloxycarbonyl or C.sub.2 -C.sub.6 -alkenyloxycarbonyl, and X=oxygen, sulfur or selenium, a process for their preparation and pharmaceutical compositions containing the compounds.
Synthesis and activity of a new class of pathway-selective estrogen receptor ligands: Hydroxybenzoyl-3,4-dihydroquinoxalin-2(1H)-ones
作者:Paige E. Mahaney、Michael B. Webb、Fei Ye、Joseph P. Sabatucci、Robert J. Steffan、Christopher C. Chadwick、Douglas C. Harnish、Eugene J. Trybulski
DOI:10.1016/j.bmc.2006.01.001
日期:2006.5
The anti-inflammatory activity of non-selective estrogens has been attributed to their ability to antagonize the activity of nuclear factor KB (NF-kappa B), a known mediator of inflammatory responses. Here we report the identification of a potent new class of pathway-selective ER ligands that selectively antagonize NF-kappa B functional activity, while exhibiting a lack of classical estrogenic effect. (c) 2006 Elsevier Ltd. All rights reserved.